The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
Open accessAbstract
Liver fibrosis is the most important predictor of mortality in nonalcoholic fatty liver disease (NAFLD). Quantitative risk of mortality by fibrosis stage has not been systematically evaluated. We aimed to quantify the fibrosis stage–specific risk of all‐cause and liver‐related mortality in NAFLD. Through a systematic review and meta‐analysis, we identified five adult NAFLD cohort studies reporting fibrosis stage–specific mortality (0‐4). Using fibrosis stage 0 as a reference population, fibrosis stage–specific mortality rate ratios (MRRs) with 95% confidence intervals (CIs) for all‐cause and liver‐related mortality were estimated. The study is reported according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement. Included were 1,495 NAFLD patients with 17,452 patient years of follow‐up. Compared to NAFLD patients with no fibrosis (stage 0), NAFLD patients with fibrosis were at an increased risk for all‐cause mortality, and this risk increased with increases in the stage of fibrosis: stage 1, MRR = 1.58 (95% CI 1.19‐2.11); stage 2, MRR = 2.52 (95% CI 1.85‐3.42); stage 3, MRR = 3.48 (95% CI 2.51‐4.83); and stage 4, MRR = 6.40 (95% CI 4.11‐9.95). The results were more pronounced as the risk of liver‐related mortality increased exponentially with each increase in the stage of fibrosis: stage 1, MRR = 1.41 (95% CI 0.17‐11.95); stage 2, MRR = 9.57 (95% CI 1.67‐54.93); stage 3, MRR = 16.69 (95% CI 2.92‐95.36); and stage 4, MRR = 42.30 (95% CI 3.51‐510.34). Limitations of the study include an inability to adjust for comorbid conditions or demographics known to impact fibrosis progression in NAFLD and the inclusion of patients with simple steatosis and nonalcoholic steatohepatitis without fibrosis in the reference comparison group. Conclusion: The risk of liver‐related mortality increases exponentially with increase in fibrosis stage; these data have important implications in assessing the utility of each stage and benefits of regression of fibrosis from one stage to another. (H epatology 2017;65:1557‐1565).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degree of liver fibrosis remains the most robust histological predictor of liver-related morbidity and mortality in patients with MASLD (Dulai et al. 2017).”
From The double-edged sword of regulatory T cells in MASLD: from inflammation control to fibrosis promotion (2026) · cites this paper as Dulai et al. 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“prognosis is mostly influenced by the grade of fibrosis rather than presence/absence of NASH [9, 10].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“once a diagnosis of NASH and/or advanced fibrosis (i.e. fibrosis stage 3 or cirrhosis) and/or portal hypertension is confirmed patients are at an increased risk for liver‐related complications (i.e. hepatic decompensation and hepatocellular carcinoma) and liver‐related mortality [9, 10, 25].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The progression to NASH involves hepatocyte damage and liver inflammation, with the development of liver fibrosis being the key determinant of patient outcomes 3-9 .”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“In patients with MASLD, liver fibrosis represents the primary determinant of mortality [258–261].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · cites this paper as [259]
In the citing paper
“Among these features, the extent of fibrosis is the strongest predictor of patient mortality, and is therefore the focus of drug development efforts (13-16).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [16]
In the citing paper
“Such clinical observations, coupled with the knowledge that fibrosis is the most significant predictor of patient mortality in MASH, focus renewed attention on mechanisms of both spontaneous and pharmacologic-induced fibrosis regression (13-16), as more research is needed to develop clinical interventions that halt progression or reverse the disease.”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Stang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationChalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,854
Self-citationNonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Nonalcoholic Fatty Liver Disease
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,320
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,004
Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment
Yang, Y., Zhao, Y., Li, W., Wu, Y., Wang, X., Wang, Y., Liu, T.-M., Ye, T., Xie, Y., Cheng, Z., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112311 · Cited by 17
Alberti, G., Gana, J. C., & Santos, J. L. (2020) · Nutrients · doi:10.3390/nu12113531 · Cited by 18
Jiang, H., Chen, H. C., Lafata, K. J., & Bashir, M. R. (2021) · Radiology · doi:10.1148/radiol.2021204325 · Cited by 17
The advantages of physical exercise as a preventive strategy against NAFLD in postmenopausal women
Molina‐Molina, E., Furtado, G. E., Jones, J. G., Portincasa, P., Pedrosa, A., Teixeira, A. M., Barros, M. P., Bachi, A. L. L., & Sardão, V. A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13731 · Cited by 19
Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)
Schattenberg, J. M., & Bergheim, I. (2019) · Nutrients · doi:10.3390/nu11030588 · Cited by 17
Neuschwander‐Tetri, B. A., Akbary, K., Carpenter, D. H., Noureddin, M., & Alkhouri, N. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.04.026 · Cited by 16
Tamilwanan, S., Aziz, Z., Rong, L. Y., Bitar, A. N., Zarzour, R. A., & Alshehade, S. A. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04358-0 · Cited by 21
Okanoue, T., Yamaguchi, K., Shima, T., Mitsumoto, Y., Mizuno, M., Katayama, T., Seko, Y., Moriguchi, M., Umemura, A., Itoh, Y., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13826 · Cited by 16
Vibration-controlled Transient Elastography in NAFLD: Review Study
Ozkan, H., & Ozercan, A. M. (2022) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1365 · Cited by 16
Ting, Y., Jalaludin, M. Y., Zaini, A. A., & Mohamed, R. B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1071350 · Cited by 17
van Son, K. C., Verschuren, L., Hanemaaijer, R., Reeves, H. L., Takkenberg, R. B., Drenth, J. P. H., Tushuizen, M. E., & Holleboom, A. G. (2023) · Cancers · doi:10.3390/cancers15041308 · Cited by 17
Kawanaka, M., Nishino, K., Kawada, M., Ishii, K., Tanikawa, T., Katsumata, R., Urata, N., Nakamura, J., Suehiro, M., Haruma, K., et al. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02786-4 · Cited by 16
Cellular and Molecular Mechanisms of Liver Fibrosis in Patients with NAFLD
Sanchez, J. I., Parra, E. R., Jiao, J., Soto, L. M. S., Ledesma, D. A., Saldarriaga, Ó. A., Stevenson, H. L., & Beretta, L. (2023) · Cancers · doi:10.3390/cancers15112871 · Cited by 17
Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ
Zhang, M., Barroso, E., Ruart, M., Peña, L., Peyman, M., Aguilar-Recarte, D., Montori-Grau, M., Rada, P., Cugat, C., Montironi, C., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115623 · Cited by 16
Mechanism and Progress of Natural Products in the Treatment of NAFLD-Related Fibrosis
Li, J.-Z., Chen, N., Ma, N., & Li, M. (2023) · Molecules · doi:10.3390/molecules28237936 · Cited by 18
Francque, S., Hodge, A. D., Boursier, J., Younes, Z. H., Rodriguez‐Araujo, G., Park, G. S., Alkhouri, N., & Abdelmalek, M. F. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000335 · Cited by 16
Yeh, M., Huang, J., Dai, C., Huang, C., Yu, M., & Chuang, W. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2388790 · Cited by 16
Saha, T., Mehrotra, S., Gupta, P., & Kumar, A. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123140 · Cited by 16
Fukuda, A., Sasao, M., Asakawa, E., Narita, S., Hisano, M., Suruga, K., Ichimura‐Shimizu, M., Tsuneyama, K., Tanaka, K., & Omagari, K. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152599 · Cited by 16
Sumida, Y., Yoneda, M., Toyoda, H., Yasuda, S., Tada, T., Hayashi, H., Nishigaki, Y., Suzuki, Y., Naiki, T., Morishita, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144939 · Cited by 16
Kalveram, L., Schunck, W., Rothe, M., Rudolph, B. D., Loddenkemper, C., Holzhütter, H., Henning, S., Bufler, P., Schulz, M., Meierhofer, D., et al. (2020) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102229 · Cited by 16
Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
Finan, B., Parlee, S. D., & Yang, B. S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101153 · Cited by 16
Sun, Q., Tang, L., Wang, M., Zhu, P., Li, Y., Ma, H., Huang, O., Hong, L. L., Li, G., Byrne, C. D., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.864570 · Cited by 17
Byrne, C. D. (2022) · Diabetic Medicine · doi:10.1111/dme.14912 · Cited by 17
Boursier, J., Cassinotto, C., Hunault, G., Shili, S., Lebigot, J., Lapuyade, B., Lannes, A., Hiriart, J., Cartier, V., Bail, B. L., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.062 · Cited by 16
Yang, X., Chang, X., Wu, S., Sun, X., Zhu, X., Wang, L., Xu, Y., Yao, X., Rao, S., Hu, X., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01453-5 · Cited by 16
Franck, M., John, K., Rau, M., Geier, A., Sowa, J., Schattenberg, J. M., Demir, M., Wedemeyer, H. H., Schulze‐Osthoff, K., & Bantel, H. (2025) · Liver International · doi:10.1111/liv.70281 · Cited by 15
NAFLD and NASH: The Metabolically Diseased Liver
Armandi, A., & Schattenberg, J. M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_561 · Cited by 16
Choi, H., Lee, M. Y., Kim, H., Oh, B. K., Lee, S. J., Kang, J., Lee, S. H., Kim, B. J., Kim, B. S., Kang, J. H., et al. (2022) · BMC Public Health · doi:10.1186/s12889-022-13128-6 · Cited by 17
Younossi, Z. M., Stepanova, M., Myers, R. P., Younossi, I. M., & Henry, L. L. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.04.023 · Cited by 15
Self-citationNakamura, Y., Miyaaki, H., Miuma, S., Akazawa, Y., Fukushima, M., Sasaki, R., Haraguchi, M., Soyama, A., Hidaka, M., Eguchi, S., et al. (2022) · Hepatology International · doi:10.1007/s12072-022-10340-9 · Cited by 15
Corbin, K. D., Dagogo-Jack, S. E., Cannon, C. P., Cherney, D. Z. I., Cosentino, F., Frederich, R. C., Liu, J., Pong, A., Lin, J., Cater, N. B., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14923 · Cited by 17
O-GlycNacylation Remission Retards the Progression of Non-Alcoholic Fatty Liver Disease
Zhou, Y., Li, Z., Xu, M., Zhang, D., Ling, J., Yu, P., & Shen, Y. (2022) · Cells · doi:10.3390/cells11223637 · Cited by 15
He, W., Huang, C., Shi, X., Wu, M., Li, H., Liu, Q., Zhang, X., Zhao, Y., & Li, X. (2022) · Endocrine Connections · doi:10.1530/ec-22-0502 · Cited by 15
Matsumoto, Y., Fujii, H., Harima, M., Okamura, H., Yukawa‐Muto, Y., Odagiri, N., Motoyama, H., Kotani, K., Kozuka, R., Kawamura, E., et al. (2023) · Nutrients · doi:10.3390/nu15051175 · Cited by 15
Kovatsch, A., Honcharova‐Biletska, H., Segna, D., Steigmiller, K., Bluemel, S., Deibel, R. A., Kühlewindt, T., Leinenkugel, G., Müller, S., Furrer, E., et al. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.13980 · Cited by 15
Predicting liver-related events in NAFLD: A predictive model
Bertot, L. C., Jeffrey, G. P., Wang, Z., Huang, Y., Garas, G., Wallace, M., de Boer, B., George, J., Eslam, M., Phu, A. L., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000356 · Cited by 15
Hatto, M., Ivano, V. K., Gestic, M. A., Utrini, M. P., Chaim, F. D. M., Callejas-Neto, F., Chaim, É. A., & Cazzo, E. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06568-5 · Cited by 15
Yilmaz, Y. N. (2023) · Hepatology forum/Hepatology forum (Online) · doi:10.14744/hf.2023.2023.0011 · Cited by 15
Amjad, W., SHALAUROVA, I. Y., Garcia, E., Gruppen, E. G., Dullaart, R. P. F., DePaoli, A. M., Jiang, Z. G., Lai, M., & Connelly, M. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713332 · Cited by 14
Singh, A., Buckholz, A. P., Kumar, S. R., & Newberry, C. A. (2024) · Nutrients · doi:10.3390/nu16050658 · Cited by 17
Zhang, W., Song, W. J., Chen, W., Pan, Z., Zhang, J., Fan, L., & Li, J. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002767 · Cited by 18
Role of anti-diabetic medications in the management of MASLD
Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 17
Elimination of hcv-infection: a history with continuation
Zhdanov, K. V., Kozlov, K. V., Sukachev, V. S., Zaharenko, S. M., Karyakin, S. S., Saulevich, A. V., Lobzin, D. Y., Yaremenko, M. V., Ivanov, K. S., Lyashenko, Y. I., et al. (2018) · Journal Infectology · doi:10.22625/2072-6732-2018-10-4-6-13 · Cited by 15
LECT2, A Novel and Direct Biomarker of Liver Fibrosis in Patients With CHB
Xu, H., Li, X., Wu, Z., Zhao, L., Shen, J., Liu, J., Qin, J., Shen, Y., Ke, J., Wei, Y., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.749648 · Cited by 15
Arman, T., Baron, J. A., Lynch, K. D., White, L. A., Aldan, J., & Clarke, J. (2021) · Toxicology · doi:10.1016/j.tox.2021.153021 · Cited by 15
Gruneau, L., Ekstedt, M., Kechagias, S., & Henriksson, M. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.10.040 · Cited by 15
Self-citationJin, W., Ting, Q., Piao-piao, Y., & JinMing, W. (2022) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2022.20715 · Cited by 15
Thongtan, T., Deb, A., Vutthikraivit, W., Laoveeravat, P., Mingbunjerdsuk, T., Islam, S. R., & Islam, E. A. (2022) · Indian Journal of Gastroenterology · doi:10.1007/s12664-021-01230-3 · Cited by 15
RGS7-ATF3-Tip60 Complex Promotes Hepatic Steatosis and Fibrosis by Directly Inducing TNFα
Basak, M., Das, K., Mahata, T., Sengar, A. S., Verma, S. K., Biswas, S., Bhadra, K., Stewart, A., & Maity, B. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0174 · Cited by 16
Pitisuttithum, P., Chan, W., Goh, G. B., Fan, J., Song, M. J., Charatcharoenwitthaya, P., Duseja, A. K., Dan, Y.-Y., Imajo, K., Nakajima, A., et al. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i19.2416 · Cited by 15
Self-citationNoninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]
Bernstein, D., & Kovalic, A. J. (2022) · Metabolism Open · doi:10.1016/j.metop.2021.100158 · Cited by 17
St. Rose, K., Yan, J., Xu, F., Williams, J., Dweck, V., Saxena, D., Schwabe, R. F., & Caviglia, J. M. (2022) · Hepatology Communications · doi:10.1002/hep4.2035 · Cited by 14
Akbary, K., Noureddin, M., Ren, Y., Tai, D., & Boudes, P. F. (2025) · Liver International · doi:10.1111/liv.70258 · Cited by 14
The many pathways driving liver inflammation in MASH
Tilg, H., Adolph, T. E., Romeo, S., & Loomba, R. S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.018 · Cited by 17
Self-citationGrobbee, E. J., de Jong, V., Schrieks, I. C., Tushuizen, M. E., Holleboom, A. G., Tardif, J., Lincoff, A. M., Schwartz, G. G., Cabezas, M. C., & Grobbee, D. E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277706 · Cited by 14
RetractedLi, Y., Lei, R., Lei, H., Qin, X., Xie, F., Yao, C., & Feng, P. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002471 · Cited by 15
Non-invasive assessment of metabolic dysfunction–associated fatty liver disease
Kumar, C. V. C., Skantha, R., & Chan, W. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221139614 · Cited by 14
Luo, Y., Wang, C., Zhang, T., He, X., Hao, J., Shen, A., Zhao, H., Chen, S., & Ren, L. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s395948 · Cited by 14
Li, Y., Zhang, L., Jiao, J., Ding, Q., Li, Y., Zhao, Z., Luo, J., Chen, Y., Ruan, X. Z., & Zhao, L. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166800 · Cited by 16
Villarroel, C., Karim, G., Sehmbhi, M., Debroff, J., Weisberg, I. S., & Dinani, A. M. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.008 · Cited by 14
Sanchez-Quant, E., Richter, M., Martinez‐Jimenez, C. P., & Colomé‐Tatché, M. (2022) · Genome biology · doi:10.1016/s0168-8278(22)01138-2 · Cited by 18
Lee, H. W., Kim, K. H., Ahn, S. H., Lee, H. C., & Choi, J. (2024) · Liver International · doi:10.1111/liv.15897 · Cited by 14
Exploring non-invasive diagnostics for metabolic dysfunction-associated fatty liver disease
Qu, B., & Li, Z. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i28.3447 · Cited by 16
Fishman, J., Kim, Y., Parisé, H., Bercaw, E., & Smith, Z. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2393952 · Cited by 14
Mann, J. P., Carter, P., Armstrong, M. J., Abdelaziz, H. K., Uppal, H., Patel, B., CHANDRAN, S. R., More, R. S., Newsome, P. N., & Potluri, R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241357 · Cited by 14
Hepatic Steatosis: An Incidental Finding That Deserves Attention
Kontrick, A. V., VanWagner, L. B., Yeh, C., & Courtney, D. M. (2020) · Academic Emergency Medicine · doi:10.1111/acem.14174 · Cited by 14
Biochemical assessment of metabolic associated fatty liver disease
Guerra-Ruiz, A. R., Casals, G., Iruzubieta, P., Lalana, M., Leis, A., López, R. M., Crespo, J., & Morales‐Ruiz, M. (2021) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2021-0009 · Cited by 14
Zaharia, O., Kupriyanova, Y., Karusheva, Y., Markgraf, D. F., Kantartzis, K., Birkenfeld, A. L., Trenell, M. I., Sahasranaman, A., Cheyette, C., Kössler, T., et al. (2021) · European Journal of Nutrition · doi:10.1007/s00394-021-02521-3 · Cited by 14
Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol
Nasr, P., Iredahl, F., Dahlström, N., Rådholm, K., Henriksson, P., Cedersund, G., Leinhard, O. D., Ebbers, T., Alfredsson, J., Carlhäll, C., et al. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01763-z · Cited by 13
Self-citationAlrasheed, M. A., Guo, J. J., Lin, A. C., Wigle, P. R., Hardee, A. M., & Hincapie, A. L. (2022) · Quality of Life Research · doi:10.1007/s11136-022-03090-6 · Cited by 14
The Non-Invasive Ultrasound-Based Assessment of Liver Viscosity in a Healthy Cohort
Popa, A., Sporea, I., Bende, F., Popescu, A., Fofiu, R., Borlea, A., Bâldea, V., Pascu, A., Foncea, C. G., Cotrău, R., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12061451 · Cited by 16
Fourman, L. T., Stanley, T. L., Ockene, M. W., McClure, C. M., Toribio, M. P., Corey, K. E., Chung, R. T., Torriani, M., Kleiner, D. E., Hadigan, C. M., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac475 · Cited by 14
Jiang, L.-P., & Sun, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1051807 · Cited by 18
Younossi, Z. M., Karrar, A., Pierobon, M., Birerdinc, A., Stepanova, M., Abdelatif, D., Younoszai, Z., Jeffers, T., Felix, S. C., Jeiran, K., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1136-1 · Cited by 15
Self-citationImpact of Non-Alcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus
Labenz, C., Kostev, K., Alqahtani, S. A., Galle, P. R., & Schattenberg, J. M. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1378-4679 · Cited by 14
Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners
Canivet, C. M., Smati, S., Lannes, A., Brisseau, J., Judon, L., Roch, M. L., Cariou, B., Bellanger, W., Guerci, B., & Boursier, J. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101848 · Cited by 14
Referral pathways for NAFLD fibrosis in primary care – No longer a ‘needle in a haystack’
Armstrong, M. J., & Marchesini, G. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.010 · Cited by 14
Diabetes mellitus and comorbidities: A bad romance
Katsiki, N., & Tousoulis, D. M. (2020) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2020.02.009 · Cited by 15
Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?
Neokosmidis, G., Cholongitas, Ε., & Τζιόμαλος, Κ. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i39.6522 · Cited by 13
Lian, N., Wu, J., Wang, B., Lin, S., Huang, J., Chen, J., & Lin, Q. (2022) · Nature and Science of Sleep · doi:10.2147/nss.s388203 · Cited by 13
Nonalcoholic Fatty Liver Disease
Yip, T. C., Wong, G. L., Wong, V. W., Goh, G. B., & Chan, W. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.12.003 · Cited by 15
Self-citationRole of Liver Biopsy in Clinical Trials and Clinical Management of Nonalcoholic Fatty Liver Disease
Goodman, Z. D. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.017 · Cited by 13
He, W., Huang, Y., Shi, X., Wang, Q., Wu, M., Li, H., Liu, Q., Zhang, X., Huang, C., & Li, X. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04300-6 · Cited by 13
Crudele, L., Matteis, C. D., Graziano, G., Novielli, F., Petruzzelli, S., Piccinin, E., Gadaleta, R. M., Cariello, M., & Moschetta, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-44243-y · Cited by 13
Raggi, P., Milić, J., Manicardi, M., Cinque, F., Swain, M. G., Sebastiani, G., & Guaraldi, G. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117523 · Cited by 14
Self-citationPanzeri, D., Laohawetwanit, T., Akpınar, R., Carlo, C. D., Belsito, V., Terracciano, L., Aghemo, A., Pugliese, N., Chirico, G. G., Inverso, D., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000695 · Cited by 14
Shi, Y. W., Wang, Q. Y., Zhao, X., Sun, Y. M., Kong, Y., Ou, X. J., Jia, J. D., Wu, S., & You, H. (2020) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12868 · Cited by 13
Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis
Tincopa, M. A. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.177 · Cited by 13
Dose–response association of the ZJU index and fatty liver disease risk: A large cohort in China
Li, X., Qin, P., Cao, L., Lou, Y., Shi, J. C., Zhao, P., Wang, C., Ma, J., Xu, S., Peng, X., et al. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15286 · Cited by 13
Non-alcoholic fatty liver disease: digest 2021
Сергеевна, К. Т., & Livzan, V. A. (2021) · Russian Journal of Evidence-Based Gastroenterology · doi:10.17116/dokgastro20211002127 · Cited by 13
Complications of lipodystrophy syndromes
Akıncı, G., Güler, M. Ç., & Akıncı, B. (2021) · La Presse Médicale · doi:10.1016/j.lpm.2021.104085 · Cited by 16
Namisaki, T., Kaji, K., Shimozato, N., Kaya, D., Ozutsumi, T., Tsuji, Y., Fujinaga, Y., Kitagawa, K., Furukawa, M., Sato, S., et al. (2022) · Indian Journal of Gastroenterology · doi:10.1007/s12664-021-01220-5 · Cited by 13
Korkiakoski, A., Käräjämäki, A. J., Ronkainen, J., AUVINEN, J. P., Hannuksela, J., Kesäniemi, Y. A., & Ukkola, O. H. (2022) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2022.2059698 · Cited by 13
Liver Fibrosis Indices Predict the Severity of SARS-CoV-2 Infection
Crudele, L., Novielli, F., Petruzzelli, S., Battaglia, S., Giuliano, A. F. M., Melodia, R., Morano, C. M., Dell'Aquila, P., Moretti, R., Castorani, L., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185369 · Cited by 13
Noninvasive Tests Used in Risk Stratification of Patients with Nonalcoholic Fatty Liver Disease
Henry, L. L., Eberly, K. E., Shah, D., Kumar, A. R., & Younossi, Z. M. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.022 · Cited by 13
Self-citationThe diagnosis of nonalcoholic fatty liver disease should carry important prognostic information
Rowe, I. A. C., & Parker, R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0168-0 · Cited by 13
Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates
Samji, N. S., Heda, R. P., & Satapathy, S. K. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.09.09 · Cited by 13
Modifiers of Liver-Related Manifestation in the Course of NAFLD
Nasr, P., Blomdahl, J., Kechagias, S., & Ekstedt, M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200310142803 · Cited by 13
Self-citationPοlyzos, S. A., & Goulas, A. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110379 · Cited by 13
Metadata
- Authors
- Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., Stal, P., Wong, V. W., Kechagias, S., Hultcrantz, R., & Loomba, R.
- Affiliations
- University of California San Diego (US)
- Mayo Clinic (US)
- Inova Fairfax Hospital (US)
- McGill University Health Centre (CA)
- Linköping University (SE)
- Department of Gastroenterology and Hepatology,Karolinska University Hospital, Karolinska Institutet,Stockholm,Sweden
- Karolinska University Hospital (SE)
- Chinese University of Hong Kong (HK)
- Corresponding author
- Loomba, Rohit
- ORCID
- Venue
- Hepatology
- Published
- 2017-03-31
- Volume
- 65
- Issue
- 5
- Pages
- 1557-1565
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- PMC
- PMC5397356
- OpenAlex
- W2580009538
- Cited by
- 1,965
- References
- 23
- Citations by year
- 2026: 199 · 2025: 193 · 2024: 227 · 2023: 263 · 2022: 240 · 2021: 272 · 2020: 249 · 2019: 163 · 2018: 101 · 2017: 48
- FWCI
- 20.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Gilead Sciences
- American Gastroenterological Association (R01‐DK106419, K23DK090303, 5T32DK007202)
- National Institutes of Health
- Fonds de Recherche du Québec - Santé
- National Institute of Diabetes and Digestive and Kidney Diseases (DK090303, R01DK106419, T32DK007202, K23DK090303)
- National Institute of Environmental Health Sciences (P42ES010337)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- non-alcoholic fatty liver disease, liver fibrosis, fibrosis stage, mortality risk, all-cause mortality, liver-related mortality, NAFLD progression, simple steatosis, nonalcoholic steatohepatitis, comorbidities, mortality prediction model, liver cancer, liver cirrhosis
- MeSH terms
- Fibrosis, Humans, Liver, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
